Purchases are not available yet. You can browse the site and sign in.
Albert Hofmann Psilocybin Isolation: The 1958 Discovery · Microdosing College
Substances
How Psilocybin Was First Isolated From Psilocybe mexicana
By Microdosing College Editorial·Last updated June 4, 2026·7 min read
Albert Hofmann's isolation of psilocybin in 1958 is the founding moment of modern psilocybin science. Working at Sandoz Laboratories in Basel — the same institution where he had first synthesised LSD fifteen years earlier — Hofmann applied classical natural-products chemistry to dried samples of Psilocybe mexicana Heim and extracted two psychoactive compounds from a fungus that indigenous Mazatec communities in Oaxaca, Mexico had used ceremonially for centuries. The paper he co-authored, published in Experientia in 1958, gave psilocybin its name, its chemical structure, and, for the first time, a reproducible synthesis route (Hofmann et al., 1958, Experientia, PubMed).
This article traces that process, explains why was the species Hofmann worked with, and shows why the 1958 isolation still shapes the .
The path to Hofmann's laboratory began with French mycologist Roger Heim. In 1955, ethnomycologist R. Gordon Wasson and photographer Allan Richardson became among the first Westerners to participate in a Mazatec mushroom ceremony led by curandera María Sabina in Huautla de Jiménez, Oaxaca. Wasson brought back samples; Heim identified and cultivated the species in Paris, naming it Psilocybe mexicana Heim. Sandoz received Heim's cultivated specimens — both dried mushroom material and living cultures — and in 1957 tasked Hofmann's group with finding the active constituents.
The choice of P. mexicana was therefore circumstantial rather than systematic: it was the species Heim could grow reliably and ship. Many other psychoactive Psilocybe species exist, but P. mexicana is one of relatively few that naturally forms sclerotia — the dense underground storage bodies now sold legally in the Netherlands as "magic truffles." The connection between Hofmann's 1958 work and today's legal truffle market is therefore direct: the same species, the same alkaloids.
The 1958 isolation: methods and findings
Hofmann's team worked with roughly 2.4 kilograms of dried P. mexicana fruiting bodies. The standard natural-products workflow of the era involved solvent extraction, chromatographic separation, and bioassay-guided fractionation — that is, the researchers tested each fraction on themselves and on animals to identify which one caused the psychoactive effect, then worked backward to purify it further.
The main compound isolated was a phosphorylated tryptamine that Hofmann named psilocybin (from Psilocybe). A second, less stable compound present in smaller amounts was named psilocin. Hofmann showed that psilocybin is the 4-phosphoryloxy derivative of dimethyltryptamine (technically O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine), and that psilocin is simply psilocybin stripped of its phosphate group. Because psilocybin is more stable than psilocin, it predominates in dried material; psilocin forms enzymatically when the phosphate group is cleaved — including, critically, in the human gut after ingestion. That metabolic conversion is now a foundational fact in understanding how these substances work (see Psilocybin vs. psilocin: what is the difference?).
The American Chemical Society, summarising the discovery in its Molecule of the Week series, notes that Hofmann then achieved a total chemical synthesis of psilocybin — confirming the structure beyond doubt and, in principle, making large-scale pharmaceutical production possible without relying on fungal cultivation (ACS, Molecule of the Week: Psilocybin). Sandoz patented the synthesis and produced psilocybin for research under the trade name Indocybin throughout the late 1950s and 1960s, until the wave of legal restrictions that followed the cultural upheavals of that decade largely shut down clinical research.
Albert Hofmann and the chemistry of the 1958 paper
Hofmann was already the world's most prominent psychedelic chemist before the P. mexicana work. His 1943 accidental self-experiment with LSD (lysergic acid diethylamide, synthesised in 1938) had established both his personal familiarity with profound altered states and Sandoz's willingness to investigate psychoactive natural products. That background mattered: when the P. mexicana fractions reached the bioassay stage, Hofmann and colleagues were willing to ingest them at doses that revealed subjective effects, which accelerated identification.
The 1958 paper listed co-authors Roger Heim (the mycologist who cultivated the specimens), Arthur Brack, Hans Kobel, A. Frey, H. Ott, J. Petrzilka, and R. Troxler — a multi-disciplinary team of chemists, a mycologist, and a pharmacologist. The collaboration illustrates how mid-century pharmaceutical research integrated disciplines in ways that are now standard but were relatively novel then.
From a chemistry standpoint, psilocybin's structure is notably simple. It belongs to the tryptamine class, shares its core with the neurotransmitter serotonin, and differs from DMT only by a 4-hydroxy group and a phosphate esterification. That structural simplicity has made it attractive for modern synthetic pharmaceutical programmes, where chemical synthesis bypasses the variability inherent in fungal cultivation — a tension at the heart of the whole-truffle versus synthetic psilocybin debate.
What Psilocybe mexicana contributes to the truffle context today
Although Hofmann worked with fruiting body (mushroom cap and stem) material, Psilocybe mexicana is one of only a handful of Psilocybe species capable of producing sclerotia — the hardened mycelial masses that the Dutch legal system distinguishes from mushrooms. A 2013 analytical study published in Drug Testing and Analysis confirmed that psilocybin and psilocin are present in sclerotia of P. tampanensis and related species at concentrations broadly comparable to dried mushrooms, underscoring that the sclerotium is not a loophole around potency but a genuine delivery form of the same alkaloids (Pellegrini et al., 2013, Drug Testing and Analysis).
For a close comparison of P. mexicana sclerotia and the more common P. tampanensis sclerotia (the "Philosopher's Stone") sold in Dutch smartshops, see Psilocybe tampanensis vs. mexicana truffles.
Beyond psilocybin and psilocin, the 1958 paper acknowledged trace compounds that Hofmann could not fully characterise with the tools available. Decades later, researchers identified baeocystin, norbaeocystin, aeruginascin, and other minor tryptamines in various Psilocybe species. A 2025 review in Pharmaceuticals (Basel) provides an up-to-date account of the full alkaloid spectrum now attributed to the genus (Vargas-Maya et al., 2025, Pharmaceuticals 18(7):989), including the minor compounds whose potential "entourage" interactions with psilocybin remain an active area of inquiry.
Why this history matters for education and harm reduction
Understanding the 1958 isolation matters for several reasons that go beyond historical curiosity.
Provenance of dosing knowledge. The doses used in early Sandoz research, and later in clinical trials at Johns Hopkins, NYU, and Imperial College London, were calibrated against synthetic psilocybin of known purity. Translating those doses to whole truffles is non-trivial because truffle alkaloid content varies by species, batch, storage duration, and preparation method. That gap between a milligram-precise pharmaceutical and a fresh or dried truffle is why accurate weighing and careful sourcing matter.
Stability context. Hofmann worked with dried material partly for practical reasons; drying concentrates alkaloids and prevents microbial degradation. Modern stability research confirms that psilocybin degrades measurably when exposed to light, heat, or humidity — the same chemistry that made Hofmann's dried specimens amenable to extraction makes proper home storage relevant to anyone using truffles today.
The single-compound assumption. Hofmann isolated two compounds; he was not aware of baeocystin or aeruginascin. Clinical trials have predominantly used highly purified synthetic psilocybin. Whether the minor alkaloids in whole truffles modify the experience in meaningful ways is a question the 1958 paper could not answer and that current research has not definitively resolved. Treating Hofmann's finding as the complete picture of what truffles contain would be an overreach — which is why we cover the full alkaloid picture separately.
If you are considering psilocybin for any health-related reason, please use the self-screener before proceeding and review the clinical evidence at /research. No compound is simply "safe," and the historical significance of psilocybin's isolation does not remove the need for careful individual assessment.
Albert Hofmann and colleagues at Sandoz Laboratories in Basel first isolated psilocybin and psilocin from dried Psilocybe mexicana fruiting bodies in 1958. The findings were published that year in the journal Experientia (Hofmann et al., 1958, PubMed ID 13537892).
What species did Hofmann use, and is it related to modern truffles?+
Hofmann worked with Psilocybe mexicana, a species identified and cultivated by French mycologist Roger Heim from samples collected in Oaxaca, Mexico. P. mexicana is one of the few Psilocybe species that naturally forms sclerotia — the underground bodies sold legally as truffles in the Netherlands today.
What exactly did the 1958 paper discover?+
The paper isolated two compounds: psilocybin (a phosphorylated tryptamine) and psilocin (psilocybin without its phosphate group). Hofmann also achieved a total chemical synthesis of psilocybin, confirming the structure and enabling pharmaceutical production. The American Chemical Society's Molecule of the Week archive summarises the discovery and structure.
Did Hofmann test psilocybin on himself?+
Yes. As with his earlier work on LSD, Hofmann's team used self-experimentation during the bioassay-guided fractionation process to identify which chemical fractions produced subjective effects. This was standard practice in mid-century natural-products pharmacology.
Are truffles sold today chemically the same as what Hofmann isolated?+
The two main compounds Hofmann identified — psilocybin and psilocin — are present in modern truffles. However, truffles also contain minor alkaloids such as baeocystin and aeruginascin that the 1958 methods could not fully characterise. A 2025 review in Pharmaceuticals (Vargas-Maya et al.) gives an up-to-date account of the full Psilocybe alkaloid spectrum.
This guide is general educational information about microdosing, not medical advice and not a recommendation to use any substance. It can't account for your personal health. If you take medication or live with a mental-health condition, speak with a qualified professional before making any decision.
